| Identification | Back Directory | [Name]
3-(2,4-dimethoxybenzylidene)anabaseine | [CAS]
156223-05-1 | [Synonyms]
DMXB
DMXB-A
GTS-21HCl
GTS 21 2HCl
DMBX-anabaseine
GTS-21 (DMXB-A)
GTS 21 2HCl(DMXBA)
GTS21;GTS 21;GTS-21
GTS 21 2hydrochloride
GTS-21 (hydrochloride)
GTS 21 dihydrochloride
3-(2,4-dimethoxybenzylidene)anabaseine
3-(2,4)-DiMethoxybenzylidineanabaseine
GTS 21 DIHYDROCHLORIDE;DMXB-A;DMBX-ANABASEINE
3-(2,4-Dimethoxybenzylidene)-anabaseine dihydrochloride
3-(2,4-Dimethoxy-benzyl)-3,4,5,6-tetrahydro-[2,3']bipyridinyl
3-(2,4-DiMethoxy-benzyl)-3,4,5,6-tetrahydro-[2,3']bipyridinyl Dihydrochloride
3-[(2,4-dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-2,3'-Bipyridine Dihydrochloride
(3E)-3-[(2,4-Dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-2,3'-Bipyridine dihydrochloride
3-[(3E)-3-[(2,4-dimethoxyphenyl)methylidene]-5,6-dihydro-4H-pyridin-2-yl]pyridine dihydrochloride | [Molecular Formula]
C19H22Cl2N2O2 | [MDL Number]
MFCD00941364 | [MOL File]
156223-05-1.mol |
| Chemical Properties | Back Directory | [Melting point ]
216-217℃ (decomposition) | [storage temp. ]
2-8°C | [solubility ]
H2O: >5mg/mL | [form ]
powder | [color ]
faint yellow to dark yellow | [Water Solubility ]
H2O: >5mg/mL | [InChIKey]
RPYWXZCFYPVCNQ-RVDMUPIBSA-N |
| Hazard Information | Back Directory | [Uses]
GTS-21 has been used:
- as an α7 nicotinic acetylcholine receptors (nAChR) partial agonist to elucidate its anti-inflammatory effects in mouse macrophages
- to test its protective effect on the renal injury induced by lipopolysaccharide (LPS)
- to test its effect on microvascular inflammation?in endotoxemia induced by LPS
| [Biochem/physiol Actions]
GTS-2, a derivative of anisine is an immunomodulatory drug. It is used for treating pancreatitis and septicemia. GTS-2 inhibits the pro-inflammatory cytokines especially the interleukin-6 (IL6) and tumor necrosis factor (TNF) in sepsis and endotoxemia. | [in vivo]
GTS 21 (4 mg/kg; i.p.; 1, 3, 7, 14 and 21 days) reduces radiation induced histological signs of pulmonary injury[3]. | Animal Model: | C57BL6 mice were irradiated with 12 Gy to induce a mouse model of Radiation induced lung injury (RILI)[3] | | Dosage: | 4 mg/kg | | Administration: | I.p.; 1, 3, 7, 14 and 21 days | | Result: | Reduces lung inflammatory infiltrate and fibrosis in radiation treated mice.
|
| [IC 50]
α7-nAChR; human α4β2: 20 nM (Ki); 5-HT3A Receptor: 3.1 μM (IC50) | [storage]
Store at -20°C |
|
|